- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
FDA Receives New Drug Application for Ivosidenib in IDH1+ Cholangiocarcinoma
March 01, 2021
A New Drug Application was submitted to the FDA for ivosidenib tablets as a potential treatment option for patients with previously treated IDH1-mutated cholangiocarcinoma. The company is requesting Priority Review be granted to the application.
FDA Issues CRL for Oral Paclitaxel and Encequidar for Metastatic Breast Cancer
March 01, 2021
The FDA has issued a complete response letter to Athenex, Inc, regarding the New Drug Application for oral paclitaxel in combination with encequidar for the treatment of metastatic breast cancer. The FDA stated that the application review process has been completed, but the NDA is not ready for approval due to safety and efficacy concerns.
AON Announces Alliance With Greater Washington Oncology Associates
March 01, 2021
American Oncology Network, LLC has announced that the Greater Washington Oncology Associates in Silver Spring, MD, joined AON effective March 1, 2021.
FDA Issues EUA for Third COVID-19 Vaccine
February 28, 2021
The FDA has issued an emergency use authorization for a third vaccine, the Janssen COVID-19 Vaccine, for the prevention of COVID-19 caused by SARS-CoV-2.
Expert Explains Why He Uses BV Plus AVD Instead of BEACOPP in Hodgkin Lymphoma
February 27, 2021
During a Targeted Oncology Case-Based Roundtable, Andrew M. Evens, DO, MSc, discussed testing and treatment for a 22-year-old patient with Hodgkin lymphoma.
FDA Approves Melflufen Combination for Triple-Class Refractory Multiple Myeloma
February 27, 2021
The FDA has granted approval to melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
MYC-Targeted Agent Dosed in First Patient in Early-Phase Solid Tumor Study
February 26, 2021
The first patient has been dosed in the phase 1/2 clinical trial of an oral CDK9 inhibitor targeting MYC-amplified solid tumors known as KB-0742.
A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care
February 26, 2021
The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
February 26, 2021
David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, reviews the combination therapies available for the treatment of multiple myeloma in a patient who is 72-years-old and transplant-ineligible.
Common and Severe Adverse Events Related to Immunotherapy for Lung Cancer
February 26, 2021
Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.
Cabozantinib Lands Breakthrough Therapy Designation in RAI-Refractory Differentiated Thyroid Cancer
February 26, 2021
The FDA has granted Breakthrough Therapy Designation to cabozantinib for the potential treatment of patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory if eligible for radioactive iodine.
SIERRA Trial Aims to Address Medical Needs for Older Patients with R/R AML
February 26, 2021
Sergio Giralt, MD, discusses the current unmet medical needs for patients with relapsed/refractory acute myeloid leukemia.